Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993237 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02993237 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 27 participants.
The verdict
NCT02993237, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the acceptability of swallowing the darunavir/cobicistat (DRV/COBI) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets, using matching placebo tablets, in human immunodeficiency virus (HIV) -1 infected adolescent patients.
Interventions
- DRUG DRV/COBI FDC placebo tablet
- DRUG D/C/F/TAF FDC placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993237
The ClinicalTrials.gov registry entry for NCT02993237 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DRV/COBI FDC placebo tablet is the first listed.
NCT02993237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993237 about?
NCT02993237 is a clinical study titled "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets". The primary purpose of this study is to assess the acceptability of swallowing the darunavir/cobicistat (DRV/COBI) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets, using matching placebo tablets, in human immunodeficiency virus (HIV) -1 i...
What is the current status of trial NCT02993237?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-01-23. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02993237?
The interventions under investigation include: DRV/COBI FDC placebo tablet (DRUG), D/C/F/TAF FDC placebo tablets (DRUG).
Who is sponsoring clinical trial NCT02993237?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.